Recombinant bispecific antibodies for cancer therapy
- 1 January 2005
- journal article
- review article
- Published by Springer Science and Business Media LLC in Acta Pharmacologica Sinica
- Vol. 26 (1), 1-9
- https://doi.org/10.1111/j.1745-7254.2005.00008.x
Abstract
Bispecific antibodies can serve as mediators to retarget effector mechanisms to disease-associated sites. Studies over the past two decades have revealed the potentials but also the limitations of conventional bispecific antibodies. The development of recombinant antibody formats has opened up the possibility of generating bispecific molecules with improved properties. This review summarizes recent developments in the field of recombinant bispecific antibodies and discusses further requirements for clinical development.Keywords
This publication has 66 references indexed in Scilit:
- A revival of bispecific antibodiesTrends in Biotechnology, 2004
- Intradiabodies, Bispecific, Tetravalent Antibodies for the Simultaneous Functional Knockout of Two Cell Surface ReceptorsJournal of Biological Chemistry, 2003
- Efficient tumor cell lysis by autologous, tumor-resident T lymphocytes in primary ovarian cancer samples by an EP-CAM-/CD3-bispecific antibodyInternational Journal of Cancer, 2003
- Gene therapy for meningioma: improved gene delivery with targeted adenovirusesJournal of Neurosurgery, 2002
- Anti-HLA-DR/anti-DOTA Diabody Construction in a Modular Gene Design Platform: Bispecific Antibodies for Pretargeted RadioimmunotherapyCancer Biotherapy & Radiopharmaceuticals, 2001
- Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokineticsJournal of Molecular Biology, 1999
- Novel tetravalent and bispecific IgG‐like antibody molecules combining single‐chain diabodies with the immunoglobulin γ1 Fc or CH3 regionFEBS Letters, 1999
- Remodeling domain interfaces to enhance heterodimer formationProtein Science, 1997
- A single-chain bispecific Fv2 molecule produced in mammalian cells redirects lysis by activated CTLMolecular Immunology, 1996
- High Level Secretion of a Humanized Bispecific Diabody from Escherichia coliNature Biotechnology, 1996